These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19906524)

  • 21. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
    Awada A; Mano M; Hendlisz A; Piccart M
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):53-60. PubMed ID: 14748657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
    Markman M
    Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
    Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
    Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The interferon system. A review of biological principles and clinical uses].
    Schneider FJ
    Z Gesamte Inn Med; 1986 Nov; 41(22):613-8. PubMed ID: 2436387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-Methoxyestradiol--a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents.
    Sutherland TE; Anderson RL; Hughes RA; Altmann E; Schuliga M; Ziogas J; Stewart AG
    Drug Discov Today; 2007 Jul; 12(13-14):577-84. PubMed ID: 17631253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of vitamin D and derivatives in hematological malignancies.
    Kim M; Mirandola L; Pandey A; Nguyen DD; Jenkins MR; Turcel M; Cobos E; Chiriva-Internati M
    Cancer Lett; 2012 Jun; 319(1):8-22. PubMed ID: 22193723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma.
    Pasquali S; Mocellin S
    Curr Med Chem; 2010; 17(29):3327-36. PubMed ID: 20712571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon and malignant disease--how does it work and why doesn't it always?
    Grandér D; Einhorn S
    Acta Oncol; 1998; 37(4):331-8. PubMed ID: 9743454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferons as inducers of apoptosis in malignant cells.
    Kotredes KP; Gamero AM
    J Interferon Cytokine Res; 2013 Apr; 33(4):162-70. PubMed ID: 23570382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents.
    Rowinsky EK
    Drugs; 2000; 60 Suppl 1():1-14; discussion 41-2. PubMed ID: 11129167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel pharmacological agents in clinical development for solid tumours.
    Dy GK; Haluska P; Adjei AA
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2059-88. PubMed ID: 11772306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon treatment of human malignancies--a short review.
    Einhorn S; Strander H
    Med Oncol Tumor Pharmacother; 1993; 10(1-2):25-9. PubMed ID: 7505041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon therapy in neoplastic diseases.
    Strander H; Einhorn S
    Philos Trans R Soc Lond B Biol Sci; 1982 Sep; 299(1094):113-7. PubMed ID: 6183685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma.
    Moschos S; Kirkwood JM
    Cytokine Growth Factor Rev; 2007; 18(5-6):451-8. PubMed ID: 17693125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokines: interleukin and interferon therapy in dermatology.
    Asadullah K; Sterry W; Trefzer U
    Clin Exp Dermatol; 2002 Oct; 27(7):578-84. PubMed ID: 12464153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms.
    Al-Keilani MS; Al-Sawalha NA
    Chem Res Toxicol; 2017 Oct; 30(10):1767-1777. PubMed ID: 28930444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumour actions of interferons: implications for cancer therapy.
    Parker BS; Rautela J; Hertzog PJ
    Nat Rev Cancer; 2016 Mar; 16(3):131-44. PubMed ID: 26911188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.